SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-011663 to ZeroStack Corp. (ZSTK)

ZeroStack Corp.
Date: Oct. 25, 2023 · CIK: 0001790169 · Accession: 0000000000-23-011663

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-275067

Date
October 25, 2023
Author
Dany Vaiman
Form
UPLOAD
Company
ZeroStack Corp.

Letter

United States securities and exchange commission logo October 25, 2023 Dany Vaiman Chief Financial Officer Flora Growth Corp. 3406 SW 26th Terrace, Suite C-1 Fort Lauderdale , FL 33312 Re:Flora Growth Corp. Registration Statement on Form S-1 Filed October 18, 2023 File No. 333-275067 Dear Dany Vaiman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Richard Raymer

Show Raw Text
United States securities and exchange commission logo
October 25, 2023
Dany Vaiman
Chief Financial Officer
Flora Growth Corp.
3406 SW 26th Terrace, Suite C-1
Fort Lauderdale , FL 33312
Re:Flora Growth Corp.
Registration Statement on Form S-1
Filed October 18, 2023
File No. 333-275067
Dear Dany Vaiman:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Richard Raymer